CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 47 enrolled
Drug / intervention
Radiation: Proton Therapy System (ProBeam)device
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06340815
NCT06340815N/ACompleted

Varian ProBeam Proton Therapy System Clinical Trial (Shandong)

Varian, a Siemens Healthineers Company·interventional·Posted Apr 2, 2024·Updated Mar 6, 2026

In Brief

A clinical study evaluating Radiation: Proton Therapy System (ProBeam) for Tumor, Solid. Completed, enrolled 47 participants across 1 site.

Detailed Summary

This study is prospective, single-center, single-arm objective performance criteria. This trial will be conducted with a total of 47 subjects enrolled. All of subjects will be treated with radiation therapy using the medical device Varian ProBeam Proton Therapy System (ProBeam), aim to compare the data with objective performance criteria (OPC) to evaluate the effectiveness and safety of ProBeam radiotherapy system for oncology patients, providing a clinical basis for the medical device registration.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTumor, Solid
CountriesChina
Collaborators--

Timeline

N/ACompletedFinished
2023202420252026
First PostedApr 2, 2024
Enrollment StartJul 20, 2022
Primary CompletionMar 8, 2023
Study CompletionMar 10, 2023
TodayJul 1, 2026
Enrollment to primary: 8 monthsPosted 2.2 years ago

Interventions

Radiation: Proton Therapy System (ProBeam)device

All enrolled subjects will be treated with Proton radiation therapy using the medical device Varian Proton Therapy System (ProBeam). The screening period from informed consent to enrollment is expected to be 2 weeks, while the treatment period depends on patient medical situation and treatment plan. The period after the last treatment is divided into short-term follow-up which is 90 days after treatment completion and long-term follow-up which is 5 years after treatment completion. The clinical trial with short-term follow-up fulfills the requirements for NMPA regulatory registration. All the end points claimed will be achieved in the short-term follow-up stage. The trial is defined as completion once short-term follow-up is finished. And long-term follow-up report will be submitted for future post market evaluation when requested by NMPA.